Clinical Trials
216 trialsNavitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
ALT-101
Allterum Therapeutics, Inc
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
BlueSphere Bio, Inc
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Vandevol
University Hospital, Lille
VIJAY-1
Aurigene Discovery Technologies Limited
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Hangzhou Sumgen Biotech Co., Ltd.
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
KNAN2001
Keystone Nano, Inc
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
VEN-OM
University of Illinois at Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
ATECRAB
Baylor College of Medicine
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
AML
University of Pennsylvania
SAGAN
Baylor College of Medicine
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
AbbVie
BaseCAR-01
University Hospital, Basel, Switzerland
CARLA-M19
University Hospital, Lille
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
University Health Network, Toronto
Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Kyowa Kirin Co., Ltd.
TRICAR-ALL
Baylor College of Medicine
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
POE14-01
Stanford University
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
University of Maryland, Baltimore
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Wugen, Inc.
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
Sichuan Baili Pharmaceutical Co., Ltd.